Recombinant Molecules as a New Frontier in Mucositis Therapy

Area of Science:

• Biotechnology
• Molecular Biology
• Gastroenterology

Background:

• Mucositis, a debilitating side effect of chemoradiotherapy, significantly impacts patient quality of life.
• Current symptomatic treatments for mucositis lack a gold-standard therapeutic protocol.
• Advances in biotechnology enable the development of genetically engineered probiotics for targeted therapy.

Purpose of the Study:

• To comprehensively review recombinant molecules as a biotherapeutic option for chemoradiotherapy-induced mucosal inflammation.
• To highlight the function of genetically modified bacteria as living drug delivery platforms.
• To discuss limitations and future challenges in the clinical application of these biotherapeutics.

Main Methods:

• Review of scientific literature on recombinant biotherapeutics for mucositis.
• Focus on genetically engineered bacteria producing or delivering therapeutic molecules.
• Analysis of therapeutic molecules including antimicrobial peptides, antioxidant enzymes, growth factors, and interleukin receptor antagonists.

Main Results:

• Genetically modified bacteria can serve as platforms for delivering therapeutic molecules to inflamed mucosal sites.
• Several recombinant biotherapeutics have shown promise in preclinical models.
• No recombinant biotherapeutic products have yet been commercially approved for human mucositis therapy.

Conclusions:

• Recombinant molecules delivered by genetically engineered bacteria represent an innovative biotherapeutic strategy for mucositis.
• Key limitations such as biosafety, gene expression control, and gut protection must be addressed.
• Overcoming these challenges is crucial for the future clinical success of bacterial-based mucositis therapies.